Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in early Parkinson's disease
2004-001485-41Phase 4Completed
- Sponsor
- Institute for Neurodegenerative Disorders
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind trial of levodopa and cabergoline in Parkinson's disease (PD) (2 arms), sponsored by Institute for Neurodegenerative Disorders. Primary endpoint: Striatal dopamine transporter density. Started Mar 2005; status: completed.
02
Drugs
levodopacabergoline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2004-001485-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001485-41.